Table 3

The classification of skin disease severity (0%, >0% to 3%, >3%) by joint involvement (low vs moderate-high)

BSA
0%>0% to 3%>3%TotalP valueCramer’s V
All patients
 CDAI
 Low258447256961
 Moderate/high109227245581
 Total3676745011542<0.0010.1639
 OR (95% CI)Reference1.20 (0.91, 1.58)2.27 (1.71, 3.01)
No DMARD therapy at enrolment
 CDAI
 Low295436119
 Moderate/high136173147
 Total42115109266<0.0010.2477
 OR (95% CI)Reference2.52 (1.19, 5.33)4.52 (2.10, 9.73)
csDMARDs only at enrolment
 CDAI
 Low6013471265
 Moderate/high306867165
 Total902021384300.0120.1439
 OR (95% CI)Reference1.01 (0.60, 1.72)1.89 (1.09, 3.27)
Biologic or tsDMARDs at enrolment
 CDAI
 Low156240145541
 Moderate/high609295247
 Total2163322407880.0040.1175
 OR (95% CI)Reference1.00 (0.68, 1.46)1.70 (1.15, 2.52)
  • Drug therapy was missing for 58 patients. P value for χ2 test of association.

  • BSA, body surface area; CDAI, Clinical Disease Activity Index; DMARD, disease-modifying antirheumatic drug; OR, odds ratio; csDMARD, conventional synthetic DMARD; tsDMARD, targeted synthetic DMARD.